Evidence map›Paper›PMID 42042614›Full record

ArticleMethods and protocols2026

Analytical Characterization of Pneumococcal Vaccine Conjugates Using SEC-MALS Technique.

Chloe Wright, Gowri Chellappan, Abigail Mydland, Gowthami Jagruthi Penumaka, Geetha Karengil, Harshita Seth, Anup Datta, Subhash V Kapre

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Methods and protocols, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Chloe WrightBacterial Research and Development, Inventprise, Inc., Redmond, WA 98052, USA.
Gowri ChellappanBacterial Research and Development, Inventprise, Inc., Redmond, WA 98052, USA.
Abigail MydlandBacterial Research and Development, Inventprise, Inc., Redmond, WA 98052, USA.ORCID 0009-0003-2954-1177
Gowthami Jagruthi PenumakaBacterial Research and Development, Inventprise, Inc., Redmond, WA 98052, USA.
Geetha KarengilBacterial Research and Development, Inventprise, Inc., Redmond, WA 98052, USA.
Harshita SethBacterial Research and Development, Inventprise, Inc., Redmond, WA 98052, USA.
Anup DattaBacterial Research and Development, Inventprise, Inc., Redmond, WA 98052, USA.
Subhash V KapreInventprise, Inc., Redmond, WA 98052, USA.ORCID 0009-0005-6642-1128

Funding

Gates Foundation OPP11752192017
6 · The paper itself

Abstract

BACKGROUND/

objectivesInfection from

methodsCapsular polysaccharides for serotypes (STs) 1, 3, 5, 10 A, 18 C, 24 F, and 33 F conjugated to rCRM197 carrier protein were chosen for this study.

resultsThe technique was very straightforward, with a high degree of accuracy (>90% based on standards) and repeatability (<2% RSD) for conjugate molar mass measurements. In addition, leveraging the capability of SEC-MALS for compositional analysis, we were able to get detailed information on the molecular assembly and conformation of the conjugates and further tweak the conjugation process to yield conjugates of a desired molar mass.

conclusionsThus, this study highlights the usefulness of the SEC-MALS technique for in-depth conjugate vaccine biophysical characterization, which is critical for achieving optimal product attributes, driving manufacturing consistency and vaccine potency.

Indexed as

compositional analysisconjugate vaccinesmolar massrCRM197SEC-MALSStreptococcus pneumoniae

Identifiers

PMID42042614
PMCPMC13118890

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.